Biologically active anti-nerve growth factor antibodies in commercial intravenous gammaglobulin

Journal of Autoimmunity

Volumn 28, Issue 1, 2007, Pages 24-29

  Warrington, Richard J ^a   Lewis, Keith E ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Anti NGF antibodies; Inflammation; IVIg; Nerve cell proliferation; NGF

Indexed keywords

IMMUNOGLOBULIN; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; NEUROTROPHIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN; CELL SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; INFLAMMATION; INHIBITION KINETICS; NERVE CELL; NERVE FIBER GROWTH; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN PURIFICATION;

ANIMALS; ANTIBODIES; BINDING, COMPETITIVE; CELL DIFFERENTIATION; IMMUNOGLOBULINS, INTRAVENOUS; NERVE GROWTH FACTOR; PC12 CELLS; RATS;

EID: 33847212108     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2006.11.005     Document Type: Article

References (23)

1. Warrington R.J., Wong S.K., and Ramadahin S. Normal human blood B cells can produce high affinity IgG antibodies to dsDNA that are recognized by cord blood-derived anti-idiotypic antibodies. Scand J Immunol 42 (1995) 397-406
2. Lacroix-Desmazes S., Kavesi S.V., and Mouthon L. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods 216 (1998) 117-137
3. Stanisz A.M., and Stanisz J.A. Nerve growth factor and neuroimmune interaction in inflammatory diseases. Ann N Y Acad Sci 917 (2000) 322-330
4. Freund V., and Frossard N. Nerve growth factor (NGF) in inflammation and asthma. Rev Mal Respir 21 (2004) 328-342
5. Pencelli C. Nerve growth factor and keratinocytes: a role in psoriasis. Eur J Dermatol 10 (2000) 85-90
6. Falcini F., Cerinic M.M., Ermini M., Generini S., Lombardi A., Pignone A., et al. Nerve growth factor circulating levels are increased in Kawasaki's disease: correlation with disease activity and reduced angiotensin converting enzyme levels. J Rheumatol 23 (1996) 1798-1802
7. Poletaev A.B., Molozov S.G., Zlunikin V.M., and Korzhenevskey D.A. Serum anti-S100b, anti-GFAP and anti-NGF autoantibodies of IgG class in healthy persons and patients with mental and neurological disorders. Autoimmunity 32 (2000) 33-38
8. Dicou E., and Nerriere V. Evidence that natural autoantibodies against the nerve growth factor (NGF) may be potential carriers of NGF. J Neuroimmunol 75 (1997) 200-203
9. Reynolds M., Alvares D., Middleton J., and Fitzgerald M. Neonatally wounded skin induces NGF-independent sensory neurite outgrowth in vitro. Brain Res Dev Brain Res 102 (1997) 275-283
10. Kasselman L.J., Sideris A., Bruno C., Perez W.R., Cai N., Nicoletti J.N., et al. BDNF: a missing link between sympathetic dysfunction and inflammatory disease. J Neuroimmunol 175 (2006) 118-127
11. Weeraratna A.T., Arnold J.T., George D.J., DeMarzo A., and Isaacs J.T. Rational basis for Trk inhibition therapy for prostate cancer. Prostate 45 (2000) 140-148
12. Dolle L., Oliveira M.J., Bruyneel E., Hondermark H., and Bracke M. Nerve growth factor mediates its pro-invasive effect in parallel with the release of a soluble E-cadherin fragment from breast cancer MCF-7/AZ cells. J Dairy Res 72 (2005) 20-26 (special issue)
13. Marchetti D., and Nicolson G.L. Human melanoma cell invasion: selected neurotrophin enhancement of invasion and heparanase activity. J Investig Dermatol Symp Proc 2 (1997) 99-105
14. Darabi K., Abdel-Wahab O., and Dzik W.H. Current use of intravenous immune globulin and the rationale behind it: the Massachusetts Hospital data and a review of the literature. Transfusion 46 (2006) 741-753
15. Viard I., Wehrli P., Bullani R., Schneider P., Holler N., Salomon D., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282 (1998) 490-493
16. Gill J.S., Schenone A.E., Podratz J.L., and Windebank A.J. Autocrine regulation of neurite outgrowth from PC-12 cellsby nerve growth factor. Brain Res Mol Brain Res 57 (1998) 123-131
17. Xiang Z., and Nilsson G. IgE receptor-mediated release of nerve growth factor by mast cells. Clin Exp Allergy 30 (2000) 1379-1386
18. Vassilev T., Mihaylova N., Voynova E., Nikolova M., Kazatchkine M., and Kaveri S. IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice. Clin Exp Immunol 145 (2006) 108-115
19. Allen S.J., and Dawbarn D. Clinical relevance of the neurotrophins and their receptors. Clin Sci 110 (2006) 175-191
20. Haque S., Boyce N., Thien F.C., O'Hehir R.E., and Douglass J. The role of intravenous immunoglobulin in severe steroid-dependant asthma. Intern Med J 33 (2003) 341-344
21. Rende M., Pistilli A., Stabile A.M., Terenzi A., Cattanzo A., Ungolini G., et al. Role of nerve growth factor and its receptors in non-nervous cancer growth: efficacy of a tyrosine kinase inhibitor (AG879) and neutralizing antibodies antityrosine kinase receptor A and antinerve growth factor: an in vitro and in vivo study. Anti-Cancer Drugs 17 (2006) 929-941
22. Hondermarck H. Potential role for NGF in breast cancer. Stem Cells 18 (2000) 386-387
23. Shoenfeld Y., and Krause I. IVIg for autoimmune, fibrosis, and malignant conditions. J Clin Immunol 24 (2004) 107-114